Neurogene Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Neurogene Inc. (NGNE) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $884.00 thousand for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2023-11-14
- Neurogene Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2023-09-30 was $304.00K, a 13.86% increase year-over-year.
- Neurogene Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2023-06-30 was $294.00K, a 13.51% increase year-over-year.
- Neurogene Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2023-03-31 was $286.00K, a 14.40% increase year-over-year.
- Neurogene Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-12-31 was $275.00K, a 14.11% increase year-over-year.
- Neurogene Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $1.05M, a 8.24% increase from fiscal 2021.
- Neurogene Inc. operating lease, right-of-use asset, amortization expense for fiscal 2021 was $971.00K, a 6.27% decline from fiscal 2020.
- Neurogene Inc. operating lease, right-of-use asset, amortization expense for fiscal 2020 was $1.04M, a 451.06% increase from fiscal 2019.
- Neurogene Inc. operating lease, right-of-use asset, amortization expense for fiscal 2019 was $188.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2023-09-30 | $304.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $598.00K derived: sum of 2 quarters · filed 2023-11-14 | $884.00K 10-Q · filed 2023-11-14 | $1.16M derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | $294.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $580.00K 10-Q · filed 2023-08-10 | $855.00K derived: sum of 3 quarters · filed 2023-08-10 | $1.12M derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-03-31 | $286.00K 10-Q · filed 2023-05-08 | $561.00K derived: sum of 2 quarters · filed 2023-05-08 | $828.00K derived: sum of 3 quarters · filed 2023-11-14 | $1.09M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-12-31 | $275.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $542.00K derived: sum of 2 quarters · filed 2023-11-14 | $801.00K derived: sum of 3 quarters · filed 2023-11-14 | $1.05M 10-K · filed 2023-03-20 |
| 2022-09-30 | $267.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $526.00K derived: sum of 2 quarters · filed 2023-11-14 | $776.00K 10-Q · filed 2023-11-14 | $1.02M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $259.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $509.00K 10-Q · filed 2023-08-10 | $750.00K derived: sum of 3 quarters · filed 2023-08-10 | $986.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $250.00K 10-Q · filed 2023-05-08 | $491.00K derived: sum of 2 quarters · filed 2023-05-08 | $727.00K derived: sum of 3 quarters · filed 2023-05-08 | $956.00K derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $241.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $477.00K derived: sum of 2 quarters · filed 2023-03-20 | $706.00K derived: sum of 3 quarters · filed 2023-03-20 | $971.00K 10-K · filed 2023-03-20 |
| 2021-09-30 | $236.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $465.00K derived: sum of 2 quarters · filed 2022-11-14 | $730.00K 10-Q · filed 2022-11-14 | $982.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $229.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $494.00K 10-Q · filed 2022-08-09 | $746.00K derived: sum of 3 quarters · filed 2022-08-09 | $999.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $265.00K 10-Q · filed 2022-05-09 | $517.00K derived: sum of 2 quarters · filed 2022-05-09 | $770.00K derived: sum of 3 quarters · filed 2022-05-09 | $773.00K derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $252.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $505.00K derived: sum of 2 quarters · filed 2022-03-01 | $508.00K derived: sum of 3 quarters · filed 2022-03-01 | $1.04M 10-K · filed 2022-03-01 |
| 2020-09-30 | $253.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $256.00K derived: sum of 2 quarters · filed 2021-11-04 | $784.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $531.00K 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $528.00K 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $188.00K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |